Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Izuralimab · XMAB-23104

Bispecific antibody · Immune activation, directed at Programmed cell death protein 1 (PDCD1) and Inducible T-cell co-stimulator (ICOS) · developed by Xencor

Phase 2 Most advanced trial (none active)
XNCR Developer
2 Registered trials

What is Izuralimab?

Izuralimab is a humanized, Fc-engineered bispecific antibody that binds both PD-1 and ICOS on T cells, including tumor-infiltrating lymphocytes. It blocks PD-1 engagement by PD-L1 and PD-L2 while stimulating ICOS signaling to enhance T-cell activation. It is being studied in multiple advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
XMAB-23104, XmAb23104
Drug type
Bispecific antibody
Targets
Programmed cell death protein 1 (PDCD1), Inducible T-cell co-stimulator (ICOS)
Mechanism
Immune activation, directed at Programmed cell death protein 1 (PDCD1) and Inducible T-cell co-stimulator (ICOS)
Pathways
PD-1/PD-L1 signaling blockade, ICOS-mediated T-cell co-stimulation
Therapy area
Oncology
Developer
Xencor, Inc. (XNCR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
9D2R4T39AY

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05879185 Phase 2 Sarcoma Terminated XNCR
NCT03752398 Phase 1 Melanoma (Excluding Uveal Melanoma) Completed XNCR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsCervical CarcinomaColorectal CarcinomaEndometrial CarcinomaGastric or Gastroesophageal Junction AdenocarcinomaHepatocellular CarcinomaMelanoma (Excluding Uveal Melanoma)Nasopharyngeal CarcinomaNon-small Cell Lung CarcinomaPancreatic CarcinomaRenal Cell CarcinomaSmall Cell Lung CancerSquamous Cell Carcinoma of the Head and NeckUrothelial Carcinoma

Other drugs acting on PDCD1 / ICOS

More from Xencor

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.

Follow XNCR, the company behind Izuralimab

See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XNCR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.